Clinical trials
Limited Stage Small Cell Lung Cancer clinical trials
Below are recruiting limited stage small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 472 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07554339RecruitingPhase 3
Calderasib and Durvalumab for Advanced Lung Cancer After Chemotherapy
This trial tests a combination of two drugs—calderasib (a targeted therapy) and durvalumab (an immunotherapy)—for people with a specific type of advanced lung cancer that has a KRAS G12C mutation. The goal is to prevent the cancer from coming back after standard chemotherapy and radiation treatment.
Lincoln, NebraskaAges 18 years+ - NCT07190248RecruitingPhase 3
Calderasib plus other treatments for advanced non-small cell lung cancer
This trial tests a new drug called calderasib (MK-1084) combined with other treatments for people with advanced non-small cell lung cancer that cannot be surgically removed. It aims to see if this combination works better than current options.
Birmingham, AlabamaAges 18 years+ - NCT07388524RecruitingPhase 3
Testing atezolizumab after surgery for early stage lung cancer
This trial tests if the immunotherapy drug atezolizumab can prevent early stage non-small cell lung cancer from coming back after surgery. It is for people whose tumors have high levels of a protein called PD-L1 (50% or more) and do not have certain gene changes (EGFR or ALK).
Beverly Hills, CaliforniaAges 18 years+ - NCT06096844RecruitingPhase 3
Chemo plus immunotherapy vs immunotherapy alone for older adults with advanced lung cancer
This trial compares chemotherapy combined with immunotherapy to immunotherapy alone for adults 70 and older with advanced non-small cell lung cancer that has a specific protein level (PD-L1 1-49%). It aims to find which treatment works better for this group.
Fayetteville, ArkansasAges 70 years+ - NCT07057791RecruitingPhase 2
Chemo plus immunotherapy for extensive-stage small cell lung cancer
This trial tests a combination of chemotherapy (platinum/etoposide) plus an immunotherapy drug (ivonescimab) for people with extensive-stage small cell lung cancer who have not received treatment before. The goal is to see if adding the immunotherapy improves outcomes.
Miami, FloridaAges 18 years+ - NCT07322341RecruitingPhase 2
Study of SX-682 with atezolizumab for advanced lung cancer
This trial tests a new drug combination (SX-682 plus atezolizumab) for people with advanced non-small cell lung cancer that has grown after standard treatments like immunotherapy and chemotherapy. It aims to see if the combination can help shrink or slow the cancer.
Seattle, WashingtonAges 18 years+ - NCT07288177RecruitingPhase 2
A study of Rina-S for people with non-small cell lung cancer
This trial tests a new drug called Rina-S for people with non-small cell lung cancer that has spread or can't be removed by surgery. It aims to see if the drug can shrink tumors and how safe it is.
Fountain Valley, CaliforniaAges 18 years+ - NCT07513376RecruitingPhase 3
Adjuvant vaccine plus immunotherapy for high-risk early lung cancer
This trial tests whether giving a personalized cancer vaccine (Intismeran) with or without an immunotherapy drug (pembrolizumab) after lung cancer surgery can help prevent the cancer from coming back in patients with early-stage, high-risk non-small cell lung cancer.
Sacramento, CaliforniaAges 18 years+ - NCT07158489RecruitingPhase 2
New drug combo for advanced lung cancer after immunotherapy
This trial combines gemcitabine with ivonescimab to try to overcome resistance to immunotherapy in advanced non-small cell lung cancer. It's for people whose cancer has worsened after prior immunotherapy.
BadenAges 18 years+ - NCT07155174RecruitingPhase 2
Testing new drug combo for first-line extensive small cell lung cancer
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
New Haven, ConnecticutAges 18 years+ - NCT07412262RecruitingPhase 2
Study of chidamide and ivonescimab for advanced lung cancer after immunotherapy resistance
This trial tests a combination of two drugs (chidamide and ivonescimab) for people with advanced non-small cell lung cancer that stopped responding to initial immunotherapy and has a specific protein marker (YAP) at high levels. It aims to see if this new combination can help when standard immunotherapy no longer works.
Guangzhou, GuangdongAges 18 years+ - NCT07566052RecruitingPhase 3
Comparing a new KRAS drug to docetaxel for advanced lung cancer
This trial tests a new pill (setidegrasib) against a standard chemo drug (docetaxel) for people with a specific type of advanced lung cancer that has a KRAS G12D mutation. The goal is to see which treatment works better.
Glendale, CaliforniaAges 18 years+ - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT06077760RecruitingPhase 3
Personalized cancer vaccine plus Keytruda for lung cancer after surgery
This study tests a new personalized cancer vaccine (V940) plus Keytruda versus a placebo plus Keytruda for people with non-small cell lung cancer that was removed by surgery. The goal is to see if the vaccine helps prevent the cancer from coming back.
Anchorage, AlaskaAges 18 years+ - NCT06498635RecruitingPhase 3
Immunotherapy after surgery for lung cancer with no remaining cancer
This trial tests whether giving immunotherapy (durvalumab) after surgery can help prevent lung cancer from coming back if you already had a complete response to chemo and immunotherapy before surgery. It is for people with early-stage non-small cell lung cancer who had no cancer left after treatment.
Jonesboro, ArkansasAges 18 years+ - NCT07531095RecruitingPhase 1
Combination drug trial for small cell lung cancer
This study tests three experimental drugs (tarlatamab, ZL-1310, and sometimes an immune-boosting drug) together to treat small cell lung cancer. The goal is to see if this combination can slow or shrink the cancer and help you live longer.
Goodyear, ArizonaAges 18–99 - NCT07221474RecruitingPhase 2
Study of a personalized vaccine plus chemo for lung cancer
This trial tests an experimental personalized cancer vaccine (V940) combined with pembrolizumab and chemotherapy for people with advanced squamous non-small cell lung cancer that has spread. The goal is to see if adding the vaccine helps the immune system fight the cancer better.
Tampa, FloridaAges 18 years+ - NCT07227597RecruitingPhase 1/Phase 2
Study of two experimental drugs for advanced small cell lung cancer
This study tests two experimental drugs, gocatamig and ifinatamab deruxtecan, for people with advanced small cell lung cancer. The goal is to see if this combination can help control the cancer, either as a first treatment or after initial standard therapy.
Santa Rosa, CaliforniaAges 18 years+ - NCT04933903RecruitingPhase 2
Neoadjuvant low-dose radiation plus immunotherapy before lung surgery
This trial tests whether giving low-dose focused radiation and two immunotherapy drugs before lung surgery can improve outcomes for people with operable, resectable non-small cell lung cancer. It aims to shrink or control the cancer before surgery and help reduce the chance it comes back.
Providence, Rhode IslandAges 18 years+ - NCT07191717RecruitingPhase 2
Imlunestrant and abemaciclib for early ER+ breast cancer
This trial tests whether adding two targeted drugs, imlunestrant and abemaciclib, to your usual hormone therapy can lower the chance of your breast cancer coming back. It is for people with early-stage ER+ breast cancer who have no signs of cancer on scans but have tiny amounts of tumor DNA in their blood (called ctDNA).
Los Angeles, CaliforniaAges 18 years+ - NCT07017829RecruitingPhase 2
Combination therapy for STK11-mutant lung cancer
This trial tests a new drug (GT103) combined with the approved immunotherapy drug pembrolizumab for people with advanced lung cancer that has a specific genetic change (STK11). The goal is to see if adding GT103 helps control the cancer better than pembrolizumab alone.
Buffalo, New YorkAges 18 years+ - NCT07365319RecruitingPhase 2/Phase 3
New drug combo for stage 4 lung cancer
This trial tests a new drug called EIK1001 combined with standard immunotherapy (pembrolizumab) and chemotherapy for people with stage 4 non-small cell lung cancer who have not been treated before. The goal is to see if adding EIK1001 helps shrink tumors more than the current standard treatment.
Daphne, AlabamaAges 18 years+ - NCT06922539RecruitingPhase 1
Experimental drug ST-001 nanoFenretinide for small cell lung cancer
This phase 1 trial tests an experimental drug called ST-001 nanoFenretinide for people with small cell lung cancer that has returned or not responded to standard chemotherapy. The drug is a newer form of fenretinide, which is related to vitamin A, and may work differently to attack cancer cells.
Los Angeles, CaliforniaAges 18 years+ - NCT06452277RecruitingPhase 3
Testing sevabertinib for advanced HER2-mutated lung cancer
This trial compares a new targeted drug called sevabertinib against standard chemotherapy plus immunotherapy for people with advanced non-small cell lung cancer that has a specific HER2 gene mutation. The goal is to see if sevabertinib works better and is safe.
Newport Beach, CaliforniaAges 18 years+
Hear when a new Limited Stage Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for limited stage small cell lung cancer?
- Yes. Clin2 currently lists 472 recruiting limited stage small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a limited stage small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a limited stage small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Small Cell Lung Cancer Extensive Stage
- Non-small Cell Lung Cancer Stage III
- Non Small Cell Lung Cancer
- Extensive-stage Small Cell Lung Cancer (ES-SCLC)
- Stage IIIA Non-small Cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Squamous Cell Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.